Leukemia

The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.

Kareem Abdul-Jabbar, NBA Legend and chronic myeloid leukemia (CML) survivor, provides advice for newly diagnosed patients with CML.

Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.

“You gotta swim, don't let yourself sink. Just find the horizon I promise you, it's not as far as you think.”

A study of acute lymphoblastic leukemia across the age spectrum is showing that some pediatric regimens can be successful in adults.

In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.

Why does a cancer diagnosis always come down to being a winner or a loser?

The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.

Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.

Who could have known that leukemia would transform me from the slow, old guy to the young, fit one?

In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.

I couldn't figure out how to fit in before this post. I read the blogs in the CURE community of contributors and I read the articles on the CURE home page — nothing.

Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.

The results showed a two-year overall survival rate of 98 percent with Imbruvica.

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

When tyrosine kinase inhibitors benefit patients with CML, can treatment ever be stopped? Experts are looking for an answer.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

A phase 3 study exploring Zydelig in combination with Treanda and Rituxan for patients with previously treated CLL has been stopped early following a positive interim analysis.

Michael J. Mauro, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).

Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses the diagnosis of chronic myeloid leukemia (CML).

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia (ALL).

Ed chronicles his chronic lymphocytic leukemia (CLL) story from the third person.

A survivor shares the story of his experience with chronic myeloid leukemia.

By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.

For adults with acute leukemia, CAR T cell immunotherapies, targeted drugs and pediatric chemotherapy regimens are improving outcomes.

Researchers say breakthrough blood cancer therapies are worth the high cost. Other experts disagree.

Researchers at UAB found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.

Watching, waiting and then choosing from a bevy of new treatments can be a good strategy for many with CLL.